Label: PYRIDIUM- phenazopyridine tablet, film coated 

  • Label RSS
  • NDC Code(s): 60846-517-01, 60846-520-01
  • Packager: Gemini Laboratories, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

Drug Label Information

Updated 02/14

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx Only

    CAUTION: Federal law prohibits dispensing without prescription.

    Close
  • DESCRIPTION

    Pyridium® (Phenazopyridine Hydrochloride) is light or dark red to dark violet, odorless, slightly bitter, crystalline powder. It has a specific local analgesic effect in the urinary tract, promptly relieving burning and pain. It has the following structural formula:

    Structural Formula

    C11H11N5•HCl                                                 M.W. 249.70

    Pyridium (Phenazopyridine HCl Tablets, USP) contains the following inactive ingredients: carnauba wax, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone and pregelatinized starch.

    Close
  • CLINICAL PHARMACOLOGY

    Phenazopyridine HCl is excreted in the urine where it exerts a topical analgesic effect on the mucosa of the urinary tract. This action helps to relieve pain, burning, urgency and frequency. The precise mechanism of action is not known.

    The pharmacokinetic properties of Phenazopyridine HCl have not been determined. Phenazopyridine HCl is rapidly excreted by the kidneys, with as much as 66% of an oral dose being excreted unchanged in the urine.

    Close
  • INDICATIONS AND USAGE

    Pyridium is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled.

    The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed two days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after two days. (See DOSAGE AND ADMINISTRATION section.)

    Close
  • CONTRAINDICATIONS

    Phenazopyridine HCl should not be used in patients who have previously exhibited hypersensitivity to it. The use of Phenazopyridine HCl is contraindicated in patients with renal insufficiency.

    Close
  • ADVERSE REACTIONS

    Headache, rash, pruritus and occasional gastrointestinal disturbance. An anaphylactoid-like reaction has been described. Methemoglobinemia, hemolytic anemia, renal and hepatic toxicity have been reported, usually at overdosage levels (see OVERDOSAGE section).

    Close
  • PRECAUTIONS

    General: A yellowish tinge of the skin or sclera may indicate accumulation due to impaired renal excretion and the need to discontinue therapy. The decline in renal function associated with advanced age should be kept in mind.

    NOTE: Patients should be informed that Phenazopyridine HCl produces a reddish-orange discoloration of the urine and may stain fabric. Staining of contact lenses has been reported.

    Laboratory Test Interaction: Due to its properties as an azo dye, Phenazopyridine HCl may interfere with urinalysis based on spectrometry or color reactions.

    Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term administration of Phenazopyridine HCl has induced neoplasia in rats (large intestine) and mice (liver). Although no association between Phenazopyridine HCl and human neoplasia has been reported, adequate epidemiological studies along these lines have not been conducted.

    Pregnancy Category B: Reproduction studies have been performed in rats at doses up to 50 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to Phenazopyridine HCl. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

    Nursing mothers: No information is available on the appearance of Phenazopyridine HCl, or its metabolites in human milk.

    Close
  • DOSAGE AND ADMINISTRATION

    100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.

    200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.

    When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.

    Close
  • OVERDOSAGE

    Exceeding the recommended dose in patients with good renal function or administering the usual dose to patients with impaired renal function (common in elderly patients) may lead to increased serum levels and toxic reactions. Methemoglobinemia generally follows a massive, acute overdose. Methylene blue, 1 to 2 mg/kg/body weight intravenously or ascorbic acid 100 to 200 mg given orally should cause prompt reduction of the methemoglobinemia and disappearance of the cyanosis which is an aid in diagnosis. Oxidative Heinz body hemolytic anemia may also occur, and “bite cells” (degmacytes) may be present in a chronic overdosage situation. Red blood cell G-6-PD deficiency may predispose to hemolysis. Renal and hepatic impairment and occasional failure, usually due to hypersensitivity, may also occur.

    Close
  • HOW SUPPLIED

    100 mg Tablets: Supplied in bottles of 100 (NDC 60846-517-01) counts.

    Appearance: Deep brown to maroon colored, round, film coated tablets debossed “AN” above “1” on one side and plain on the other.

    200 mg Tablets: Supplied in bottles of 100 (NDC 60846-520-01) counts.

    Appearance: Deep brown to maroon colored, round, film coated tablets debossed “AN” above “2” on one side and plain on the other.

    DISPENSE contents with a child-resistant closure (as required) and in a tight container as defined in the USP.

    STORE at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

    Manufactured for:
    Gemini Laboratories, LLC
    Bridgewater, NJ 08807

    Rev. 02-2014

    Close
  • Principal Display Panel - 100 mg Label

    NDC 60846-517-01

    Pyridium®

    (Phenazopyridine HCl
    Tablets, USP)

    100 mg

    Rx only

    100 TABLETS

    GEMINI

    LABORATORIES

    Principal Display Panel - 100 mg Label
    Close
  • Principal Display Panel - 200 mg Label

    NDC 60846-520-01

    Pyridium®

    (Phenazopyridine HCl

    Tablets, USP)

    200 mg

    Rx only

    100 TABLETS

    GEMINI

    LABORATORIES

    Principal Display Panel - 200 mg Label
    Close
  • INGREDIENTS AND APPEARANCE
    PYRIDIUM 
    phenazopyridine tablet, film coated
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:60846-517
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Phenazopyridine (Phenazopyridine) Phenazopyridine 100 mg
    Inactive Ingredients
    Ingredient Name Strength
    carnauba wax  
    croscarmellose sodium  
    hypromelloses  
    magnesium stearate  
    cellulose, microcrystalline  
    polyethylene glycols  
    povidone  
    starch, corn  
    Product Characteristics
    Color brown (maroon) Score no score
    Shape ROUND (ROUND) Size 10mm
    Flavor Imprint Code AN;1
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:60846-517-01 100 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    unapproved drug other 02/01/2011
    PYRIDIUM 
    phenazopyridine tablet, film coated
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:60846-520
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Phenazopyridine (Phenazopyridine) Phenazopyridine 200 mg
    Inactive Ingredients
    Ingredient Name Strength
    carnauba wax  
    croscarmellose sodium  
    hypromelloses  
    magnesium stearate  
    cellulose, microcrystalline  
    polyethylene glycols  
    povidone  
    starch, corn  
    Product Characteristics
    Color brown (maroon) Score no score
    Shape ROUND (ROUND) Size 10mm
    Flavor Imprint Code AN;2
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:60846-520-01 100 in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    unapproved drug other 02/01/2011
    Labeler - Gemini Laboratories, LLC (079130098)
    Close